Kinnate Biopharma Inc.
KNTEDelisted Apr 3, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001797768
Kinnate Biopharma Inc. was delisted on Apr 3, 2024; its insiders filed their last Form 4 on Apr 5, 2024; 56 institutions reported holding it in 13F filings for Q1 2024, worth $92.2M in total; Viking Global Investors was the only superinvestor holding it.
Holders of 5% or more of KNTE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kinnate Biopharma Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Kinnate Biopharma Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
31 Schedule 13D and 13G filings on Kinnate Biopharma Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Vida Ventures, LLC | 13G/AOld format | – | – | – | SEC |
| Apr 5, 2024 | Foresite Capital Fund V, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 22, 2024 | Foresite Capital Fund V, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 21, 2024 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Tang Capital Partners LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Nextech V Oncology S.C.S., SICAV-SIF | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Nov 27, 2023 | Tang Capital Partners LP | 13GOld format | – | New | – | SEC |
| Nov 17, 2023 | Foresite Capital Fund V, L.P. | 13D/AOld format | – | – | – | SEC |
| Nov 17, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Nov 14, 2023 | Foresite Capital Fund V, L.P. | 13D/AOld format | – | – | – | SEC |
| Nov 14, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Aug 14, 2023 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| May 10, 2023 | Foresite Capital Fund IV, L.P. | 13D/AOld format | – | – | – | SEC |
| May 8, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| May 3, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Apr 6, 20239:29 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 23, 2023 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 22, 2023 | Foresite Capital Fund IV, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Nextech V Oncology S.C.S., SICAV-SIF | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2023 | Vida Ventures, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 3, 20234:27 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Jan 23, 2023 | Lynx1 Capital Management LP | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Vida Ventures, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Vida Ventures, LLC | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Nextech V Oncology S.C.S., SICAV-SIF | 13GOld format | – | New | – | SEC |
| Feb 8, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Kinnate Biopharma Inc. shares.
No Form 144 notices for Kinnate Biopharma Inc. are on file.